Jefferies Maintains Bullish Stance on Dyax (DYAX) Following Meetings

Jefferies analyst Biren Amin reiterated a Buy rating and $13 price target on Dyax Corp. (NASDAQ: DYAX) following management meetings.

Amin comments, "We had the opportunity to host several investor meetings w/ DYAX management in which DX-2930 P1b should provide add'l insights into the pivotal trial due to embark in 2015. While the PIb is a standard PK/PD/safety study, there may be data on reductions of HAE attack frequency which would increase odds of a pivotal trial. DX-2930 could differentiate on improved convenience and also on increased efficacy over std of care and pipeline cmpds."

For an analyst ratings summary and ratings history on Dyax Corp. click here. For more ratings news on Dyax Corp. click here.

Shares of Dyax Corp. closed at $10.00 yesterday.

You May Also Be Interested In

• Jefferies Upgrades Medpace (MEDP) to Buy, 'Big Margin Improvements'
• JPMorgan Downgrades MP Materials (MP) to Neutral
• Informatica (INFA) PT Lowered to $40 at Wells Fargo